Links of platelet glutamate and glutathione metabolism with attenuated positive and negative symptoms in depressed patients at clinical high risk for psychosis

[1]  A. Grace,et al.  Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes , 2021, Neuropsychopharmacology.

[2]  J. Gati,et al.  Conceptual disorganization and redistribution of resting-state cortical hubs in untreated first-episode psychosis: A 7T study , 2021, npj Schizophrenia.

[3]  G. Strauss,et al.  The Latent Structure of Negative Symptoms in Individuals With Attenuated Psychosis Syndrome and Early Psychosis: Support for the 5 Consensus Domains. , 2020, Schizophrenia bulletin.

[4]  G. Burbaeva,et al.  Platelet glutamate dehydrogenase activity and efficacy of antipsychotic therapy in patients with schizophrenia , 2019, Journal of medical biochemistry.

[5]  R. Mizrahi,et al.  Validating mitochondrial electron transport chain content in individuals at clinical high risk for psychosis , 2019, Scientific Reports.

[6]  H. Häfner.  From Onset and Prodromal Stage to a Life-Long Course of Schizophrenia and Its Symptom Dimensions: How Sex, Age, and Other Risk Factors Influence Incidence and Course of Illness , 2019, Psychiatry journal.

[7]  V. Kaleda,et al.  [The activity of enzymes of glutathione metabolism in blood cells of patients with a high risk of manifestation of endogenous psychoses and patients with the first psychotic episode]. , 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[8]  V. Kaleda,et al.  [Glutathione reductase and glutathione-S-transferase in blood cells in schizophrenia and schizophrenia spectrum disorders]. , 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[9]  Siân E. Robson,et al.  Glutathione and glutamate in schizophrenia: a 7T MRS study , 2018, Molecular Psychiatry.

[10]  R. Mizrahi,et al.  Mitochondrial function in individuals at clinical high risk for psychosis , 2018, Scientific Reports.

[11]  Rolf Gruetter,et al.  N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis , 2017, Schizophrenia bulletin.

[12]  M. Birchwood,et al.  Depression and Schizophrenia: Cause, Consequence, or Trans-diagnostic Issue? , 2016, Schizophrenia bulletin.

[13]  C. Correll,et al.  Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. , 2016, Journal of psychiatric research.

[14]  M. Cuénod,et al.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? , 2016, Schizophrenia Research.

[15]  John M. Davis,et al.  Dose Equivalents for Antipsychotic Drugs: The DDD Method. , 2016, Schizophrenia bulletin.

[16]  Kim Q. Do,et al.  Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis , 2016, Nature Reviews Neuroscience.

[17]  V. Kaleda,et al.  [Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis]. , 2016, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[18]  Kyu Bong Cho,et al.  Genetic Polymorphisms of Glutathione-Related Enzymes (GSTM1, GSTT1, and GSTP1) and Schizophrenia Risk: A Meta-Analysis , 2015, International journal of molecular sciences.

[19]  T. Furukawa,et al.  Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. , 2015, Journal of affective disorders.

[20]  M. MacDonald,et al.  The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies , 2015, Annals of the New York Academy of Sciences.

[21]  G. Aleshkina,et al.  [Depressive disorders in psychopathological structure of first episode psychosis manifesting in adolescence and young adulthood]. , 2015, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[22]  F. Kapczinski,et al.  Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. , 2013, Journal of psychiatric research.

[23]  Thomas R. E. Barnes,et al.  How to compare doses of different antipsychotics: A systematic review of methods , 2013, Schizophrenia Research.

[24]  M. Laconi,et al.  Allopregnanolone and puberty: Modulatory effect on glutamate and GABA release and expression of 3α-hydroxysteroid oxidoreductase in the hypothalamus of female rats , 2013, Neuroscience.

[25]  J. Krystal,et al.  Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. , 2012, Schizophrenia bulletin.

[26]  V. Nimgaonkar,et al.  Genetic association studies of antioxidant pathway genes and schizophrenia. , 2011, Antioxidants & redox signaling.

[27]  J. Krystal,et al.  Contributions of Glutamate and GABA Systems to the Neurobiology and Treatment of Schizophrenia , 2011 .

[28]  Jun-Feng Wang,et al.  Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. , 2011, The international journal of neuropsychopharmacology.

[29]  G. Burbaeva,et al.  Platelet cytochrome c-oxidase activity in patients with acute schizophrenia in the course of their treatment with risperidone , 2011 .

[30]  A. Kerkeni,et al.  Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[31]  Michael Berk,et al.  Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. , 2009, Annals of the Academy of Medicine, Singapore.

[32]  T. Werge,et al.  Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence , 2007, Proceedings of the National Academy of Sciences.

[33]  G. Burbaeva,et al.  Systemic Neurochemical Alterations in Schizophrenic Brain: Glutamate Metabolism in Focus , 2007, Neurochemical Research.

[34]  Godfrey D Pearlson,et al.  Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. , 2003, Schizophrenia bulletin.

[35]  D. Ben-shachar,et al.  State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia , 2002, Molecular Psychiatry.

[36]  S. Deutsch,et al.  A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications , 2001, Clinical neuropharmacology.

[37]  P Boesiger,et al.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo , 2000, The European journal of neuroscience.

[38]  J B Schulz,et al.  Glutathione, oxidative stress and neurodegeneration. , 2000, European journal of biochemistry.

[39]  D. Ben-shachar,et al.  Increased mitochondrial complex I activity in platelets of schizophrenic patients. , 1999, The international journal of neuropsychopharmacology.

[40]  T. Bourgeron,et al.  Biochemical and molecular investigations in respiratory chain deficiencies. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[41]  Janet B W Williams,et al.  A structured interview guide for the Hamilton Depression Rating Scale. , 1988, Archives of general psychiatry.

[42]  H. F. Fisher.  L-Glutamate dehydrogenase from bovine liver. , 1985, Methods in enzymology.

[43]  J. Keen,et al.  Mechanism for the several activities of the glutathione S-transferases. , 1976, The Journal of biological chemistry.

[44]  J. Korf,et al.  DOPAMINE AND SCHIZOPHRENIA , 1976, The Lancet.

[45]  David J. Worthington,et al.  Glutathione Reductase from Human Erythrocytes , 1976 .